Sickle cell retinopathy screening programmes that deploy fundus cameras across multiple manufacturers face a representational problem that is rarely quantified: chromatic aberration varies systematically between devices, and a convolutional network trained on images from one camera family may encode device-specific colour profiles as if they were retinopathy features. the present analysis treats that risk as a design property of the screening pipeline rather than a nuisance to be corrected post hoc. We formalise chromatic aberration as a bounded, device-indexed perturbation operator on the retinal image manifold and define a domain-invariant representation as one whose referral decision is Lipschitz-stable under that operator. Using a before-after-control-impact design with a declared variance structure (between-cluster SD = 6.0, residual SD = 4.5, intraclass correlation = 0.64), we characterise the operating characteristics of the evaluation across 2000 replications per design cell at cluster counts of 8, 16, 24 and 32 and effect sizes of 3, 5 and 8 percentage points.54 clusters are required to detect a 5-percentage-point referral-equity effect at 80% power under this variance structure, and that the minimum detectable effect falls steeply as cluster count rises from 8 to 32. We argue that referral equity in artificial-intelligence retinopathy screening is not a property of a model alone but of the joint distribution of camera chromatic profiles and the representation's invariance class, and that evaluation designs which ignore this coupling will systematically overstate equity gains.
No takes yet. Share an insight, caveat, or question.
Sarr et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: